Clinical trial
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
NCT03505021 is registered in ClinicalTrials.gov with Orion Corporation, Orion Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
- Lead sponsor
- Orion Corporation, Orion Pharma
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 21, 2018
- Completion date
- July 23, 2020
- Enrollment
- 496 (actual)
- Sites
- 104
Conditions
As the registry lists them; a condition with its own page is linked.